Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
52.85 HKD | +1.63% | +0.38% | +48.46% |
04-30 | Giant Biogene’s Profit Up 47% in 2023 | MT |
03-26 | Giant Biogene to Pay Special 0.45 Yuan per Share Dividend | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The firm trades with high earnings multiples: 26.48 times its 2024 earnings per share.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Sector: Personal Products
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+48.46% | 6.5B | - | ||
+13.19% | 391B | C- | ||
+13.53% | 136B | B- | ||
+18.50% | 77.5B | A+ | ||
-11.35% | 66.4B | A- | ||
-7.89% | 48.3B | B+ | ||
-5.43% | 38.99B | - | ||
+8.33% | 35.51B | B- | ||
+12.28% | 18.18B | A- | ||
+17.42% | 16.39B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 2367 Stock
- Ratings Giant Biogene Holding Co., Ltd.